Astrazeneca annual debt-to-assets ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Debt-to-Assets Ratio Growth & History (AZN)
Astrazeneca's debt-to-assets ratio was 0.28 for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.28 | −0.03 | −9.73% |
| 2024 | 2024-12-31 | 0.31 | 0.01 | +3.72% |
| 2023 | 2023-12-31 | 0.29 | −0.02 | −5.96% |
| 2022 | 2022-12-31 | 0.31 | 0.01 | +3.76% |
| 2021 | 2021-12-31 | 0.30 | −0.01 | −4.47% |
| 2020 | 2020-12-31 | 0.32 | 0.01 | +2.49% |
| 2019 | 2019-12-31 | 0.31 | −0.01 | −2.27% |
| 2018 | 2018-12-31 | 0.32 | 0.03 | +12.12% |
| 2017 | 2017-12-31 | 0.28 | 0.01 | +4.56% |
| 2016 | 2016-12-31 | 0.27 | 0.02 | +7.25% |
| 2015 | 2015-12-31 | 0.25 | — | — |
Astrazeneca quarterly debt-to-assets ratio
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.28 | −0.03 | −9.23% |
| Q1 2026 | 2026-03-31 | 0.30 | — | — |
| Q4 2025 | 2025-12-31 | 0.28 | −0.03 | −9.73% |
| Q3 2025 | 2025-09-30 | 0.29 | — | — |
| Q2 2025 | 2025-06-30 | 0.31 | −0.03 | −8.00% |
| Q4 2024 | 2024-12-31 | 0.31 | 0.01 | +3.72% |
| Q2 2024 | 2024-06-30 | 0.33 | 0.01 | +4.50% |
| Q4 2023 | 2023-12-31 | 0.29 | −0.02 | −5.96% |
| Q2 2023 | 2023-06-30 | 0.32 | 0.00 | +1.21% |
| Q4 2022 | 2022-12-31 | 0.31 | 0.01 | +3.76% |
| Q2 2022 | 2022-06-30 | 0.32 | −0.07 | −17.67% |
| Q4 2021 | 2021-12-31 | 0.30 | −0.01 | −4.47% |
| Q2 2021 | 2021-06-30 | 0.38 | 0.04 | +12.51% |
| Q4 2020 | 2020-12-31 | 0.32 | 0.01 | +2.49% |
| Q2 2020 | 2020-06-30 | 0.34 | 0.01 | +3.08% |
| Q4 2019 | 2019-12-31 | 0.31 | −0.01 | −2.27% |
| Q2 2019 | 2019-06-30 | 0.33 | 0.01 | +2.93% |
| Q4 2018 | 2018-12-31 | 0.32 | 0.03 | +12.12% |
| Q2 2018 | 2018-06-30 | 0.32 | — | — |
| Q4 2017 | 2017-12-31 | 0.28 | — | — |
Astrazeneca debt-to-assets ratio trends
Over the last five fiscal years, Astrazeneca's debt-to-assets ratio decreased from 0.32 to 0.28, a change of −0.04. The latest reported quarter, Q2 2026, shows 0.28.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...